Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654633 | 0.94 | HDAC1 (0.41) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL2187729 | 0.94 | HDAC1 (0.49) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3239600 | 0.92 | HDAC1 (0.44) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3242305 | 0.91 | GRIN2D (0.50) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3241053 | 0.91 | HDAC1 (0.46) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL14733395 | 0.88 | GRIN2D (0.42) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3231442 | 0.86 | HTR6 (0.48) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3234803 | 0.86 | BCHE (0.49) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL3236149 | 0.85 | HDAC1 (0.49) | HDAC1HDAC6BCHEGRIN2DGRIN3B | |
| SCHEMBL13654623 | 0.85 | HDAC1 (0.43) | HDAC1HDAC6BCHEGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9481676-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481676-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481676-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| WO-2010051503-A1 | AZEPINO [4, 5-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HDAC1 1375/4885HDAC6 2844/4885BCHE 3838/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HDAC1 2449/4885HDAC6 3173/4885BCHE 1869/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | HDAC1 1531/4885HDAC6 1266/4885BCHE 532/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HDAC1 2415/4885HDAC6 3097/4885BCHE 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.